Summit Therapeutics Inc

+0.16 (+16.79%)
Earnings Announcements

Summit Therapeutics Reports Qtrly Basic & Diluted Loss Per Share Of $0.28

Published: 03/17/2022 20:24 GMT
Summit Therapeutics Inc (SMMT) - Summit Therapeutics Inc Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2021.
Summit Therapeutics Inc - Qtrly Basic and Diluted Loss per Share $0.28.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.27

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.28

More details on our Analysts Page.